ArticleAddiction science & clinical practice2013
Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.
Article in Addiction science & clinical practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- A meta-analysis of topiramate's effects for individuals with alcohol use disorders.Alcoholism, clinical and experimental research · 2014Pooled it
- Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials.Addiction biology · 2022Trial
- Severity of Topiramate-Related Working Memory Impairment Is Modulated by Plasma Concentration and Working Memory Capacity.Journal of clinical pharmacology · 2020Trial
- Trial
- Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.The Journal of clinical psychiatry · 2016Trial
- Primary Care Visit Frequency Is Associated With Diagnosis But Not Pharmacotherapy Prescribing for Patients With Alcohol Use Disorder : AUD Pharmacotherapy Prescribing in Primary Care.The journal of behavioral health services & research · 2025Article
- Alcohol Treatment Access and Engagement Among Women in the USA: a Targeted Review of the Literature 2012-2022.Current addiction reports · 2023Article
- Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data.Addiction (Abingdon, England) · 2022Article
- Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.Journal of substance abuse treatment · 2020Article
- Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes.Addiction science & clinical practice · 2019Article
- Primary care engagement is associated with increased pharmacotherapy prescribing for alcohol use disorder (AUD).Addiction science & clinical practice · 2019Article
- Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion.Journal of substance abuse treatment · 2018Article
- An Overview of Pharmacotherapy Options for Alcohol Use Disorder.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018Article
- Review
- Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?Neurotoxicity research · 2016Review
- Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC.Implementation science : IS · 2016Article
- Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics.Addiction science & clinical practice · 2016Article
- Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.Alcoholism, clinical and experimental research · 2015Article
- Long-term drug treatment of patients with alcohol dependence.Australian prescriber · 2015Review
- Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Experimental and clinical psychopharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a quality improvement metric, the US Veterans Health Administration (VHA) monitors the proportion of patients with alcohol use disorders (AUD) who receive FDA approved medications for alcohol dependence (naltrexone, acamprosate, and disulfiram). Evidence supporting the off-label use of the antiepileptic medication topiramate to treat alcohol dependence may be as strong as these approved medications. However, little is known about the extent to which topiramate is used in clinical practice. The goal of this study was to describe and examine the overall use, facility-level variation in use, and patient -level predictors of topiramate prescription for patients with AUD in the VHA.
methodsUsing national VHA administrative data in a retrospective cohort study, we examined time trends in topiramate use from fiscal years (FY) 2009-2012, and predictors of topiramate prescription in 375,777 patients identified with AUD (ICD-9-CM codes 303.9x or 305.0x) treated in 141 VHA facilities in FY 2011.
resultsAmong VHA patients with AUD, rates of topiramate prescription have increased from 0.99% in FY 2009 to 1.95% in FY 2012, although substantial variation across facilities exists. Predictors of topiramate prescription were female sex, young age, alcohol dependence diagnoses, engagement in both mental health and addiction specialty care, and psychiatric comorbidity.
conclusionsVeterans Health Administration facilities are monitored regarding the extent to which patients with AUD are receiving FDA-approved pharmacotherapy. Not including topiramate in the metric, which is prescribed more often than acamprosate and disulfiram combined, may underestimate the extent to which VHA patients at specific facilities and overall are receiving pharmacotherapy for AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.